UK markets open in 7 hours 46 minutes
  • NIKKEI 225

    26,491.97
    +320.77 (+1.23%)
     
  • HANG SENG

    21,719.06
    +445.16 (+2.09%)
     
  • CRUDE OIL

    106.38
    -1.24 (-1.15%)
     
  • GOLD FUTURES

    1,836.10
    +5.80 (+0.32%)
     
  • DOW

    31,500.68
    +823.28 (+2.68%)
     
  • BTC-GBP

    17,187.85
    -341.31 (-1.95%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • ^IXIC

    11,607.62
    +375.42 (+3.34%)
     
  • ^FTAS

    3,975.07
    +100.39 (+2.59%)
     

US high court denies Bayer bid to block Roundup weedkiller lawsuits

·3-min read

The US Supreme Court on Tuesday declined to hear a bid from Bayer-owned Monsanto that aimed to challenge thousands of lawsuits claiming its weedkiller Roundup causes cancer -- a potentially costly ruling.

The high court did not explain its decision, which left intact a $25 million ruling in favor of a California man who alleged he developed cancer after using the chemical for years.

The decision marks a major blow to the German conglomerate's legal fight against Roundup-related cases, and Bayer has set aside more than $15 billion to deal with a wave of US lawsuits linked to the weedkiller.

"Bayer respectfully disagrees with the Supreme Court's decision," the company said in a statement.

"The company believes that the decision undermines the ability of companies to rely on official actions taken by expert regulatory agencies," it added, referring to a 2020 federal finding that Roundup's active ingredient is not risky.

Bayer has been plagued by problems since it bought Monsanto, which owns Roundup, in 2018 for $63 billion and inherited its legal woes around the chemical's ingredient glyphosate.

The German firm says it has not committed any wrongdoing, and maintains that scientific studies and regulatory approvals show glyphosate is safe.

Glyphosate is nonetheless classified as a "probable carcinogen" by the International Agency for Research on Cancer at the World Health Organization (WHO).

- Billions in claims -

However, the United States Environmental Protection Agency, on its website, says "there are no risks of concern to human health when glyphosate is used in accordance with its current label."

The Supreme Court's decision not to intervene leaves in place Monsanto's appellate conviction in the lawsuit filed by Edwin Hardeman, who was diagnosed with non-Hodgkin's lymphoma in 2015.

In addition to the some 30,000 cases about health problems allegations against the weedkiller, Bayer's own shareholders have taken legal action as well.

Investors are seeking 2.2 billion euros ($2.5 billion) in damages in a German court for losses incurred following its troubled takeover of Monsanto, their lawyers said in January.

The investors accuse Bayer of having "misled capital markets about the economic risks from pending consumer lawsuits in the United States in connection with glyphosate and the herbicide Roundup," law firm Tilp said in a statement.

Tilp said around 320 investors have submitted complaints, most of them institutional investors such as banks, wealth managers, insurers and pension funds.

Some three-quarters of the claims targeting Roundup originate with residential consumers, and not large-scale farmers.

Bayer executives have argued that its agricultural users know the proper use of the product better than residential ones.

The firm said it is transitioning its glyphosate-based products in the US residential market to new formulations that have alternative active ingredients beginning in 2023.

"The company is taking this action exclusively to manage litigation risk in the US and not because of any safety concerns," it said in a statement.

Bayer says it has resolved around 107,000 of a total of 138,000 cases related to the herbicide.

Bayer's share price was down just under two percent after the court's decision on Tuesday.

chp/jm/sst

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting